Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.

ABSTRACT:

Objective

To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg.

Design and methods

Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥ 6 months and had normal IGF1 levels. Lanreotide Autogel 120 mg was administered every 6 weeks for 24 weeks (phase 1); depending on week-24 IGF1 levels, treatment was then administered every 4, 6 or 8 weeks for a further 24 weeks (phase 2). Hormone levels, patient-reported outcomes and adverse events were assessed.

Primary endpoint

proportion of patients on 6- or 8-week EDIs with normal IGF1 levels at week 48 (study end).

Results

107/124 patients completed the study (15 withdrew from ph

SUBMITTER: Neggers SJ 

PROVIDER: S-EPMC4544680 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature